Nuvalent Insider Offloads $424,607 of Stock, Reduces Stake by 8.9%
Nuvalent insider Deborah Ann Miller sold 4,363 shares on January 5 at an average $97.32 per share, realizing $424,607 total. After the sale her holdings fell by 8.89% to 44,723 shares valued at $4.35 million.
1. Insider Sells Over $1.1 Million in Stock
Three Nuvalent executives—Deborah Ann Miller, Christopher Durant Turner and CFO Alexandra Balcom—collectively sold 12,835 shares on January 5th and 6th, generating proceeds of approximately $1.09 million. Miller’s sale of 4,363 shares accounted for $424,607.16, Turner’s sale of 4,236 shares generated $412,247.52 and Balcom’s sale of 4,236 shares brought in $412,247.52. Following these transactions, Miller’s stake fell by 8.9% to 44,723 shares, Turner’s declined by 6.8% to 58,311 shares and Balcom’s by 4.8% to 84,914 shares—reductions that could signal near-term liquidity needs or portfolio diversification strategies by the insiders.
2. Institutional Ownership Remains High
According to the latest filings, 97.3% of Nuvalent shares are held by institutional investors and hedge funds. Notable activity in the fourth quarter included GAMMA Investing LLC boosting its position by 47.6% to 335 shares, while Farther Finance Advisors increased its stake by 9,230.8% to 1,213 shares. Smaller positions were initiated by Aster Capital Management DIFC Ltd and Eastern Bank in the third quarter, underscoring continued institutional confidence in Nuvalent’s long-term oncology pipeline.
3. Recent Earnings Miss and Forecasts Highlight Development Costs
In its fiscal fourth quarter, Nuvalent reported a loss per share of $1.70, missing analysts’ estimates by $0.31 and widening from a loss of $1.28 a year earlier. Research consensus forecasts a full-year loss per share of $3.86, reflecting ongoing R&D investments in lead candidates NVL-520 and NVL-655. Despite continued cash burn, the company maintains a market capitalization near $7.6 billion and a negative price-to-earnings ratio, characteristic of clinical-stage biopharma firms advancing late-stage clinical programs.
4. Analysts Lift Targets Amid Pipeline Progress
Fifteen analysts currently rate Nuvalent shares as a buy, with an average price target of $138.33. Recent upward revisions include Robert W. Baird raising its objective from $112 to $158 and Stifel Nicolaus increasing its target from $115 to $135. Truist Financial and Piper Sandler have likewise set targets at $140 and $128, respectively, citing positive early data on RET and KRAS G12D inhibitors. These revisions suggest growing market confidence in potential readouts from ongoing pivotal trials later this year.